BioXcel Therapeutics
BTAI
BTAI was delisted on the 4th of September, 2026.
20 hedge funds and large institutions have $24.9M invested in BioXcel Therapeutics in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
167% more capital invested
Capital invested by funds: $9.35M → $24.9M (+$15.6M)
82% more funds holding
Funds holding: 11 → 20 (+9)
0.04% more ownership
Funds ownership: 0.97% → 1% (+0.04%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$925K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$481K |
| 3 |
Renaissance Technologies
New York
|
+$345K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$235K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$195K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
-$1.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$153K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$19K |
| 4 |
Morgan Stanley
New York
|
-$12.9K |
| 5 |
BlackRock
New York
|
-$7.64K |
BTAI Hedge Fund Activity: Q1 2019 in Review
20 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2019, worth a combined $24.9M — up 167% from $9.35M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BTAI positions and 2 closed out — a net gain of 9 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $925K. The largest seller was Artemis Investment Management, cutting an estimated $1.5M.
- 20 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2019, up from 11 in Q4 2018.
- Funds reported $24.9M of BioXcel Therapeutics stock for Q1 2019, up 167% quarter-over-quarter.
- 11 funds opened new BioXcel Therapeutics positions in Q1 2019 and 2 closed out, a net change of +9 holders.
- The largest BioXcel Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $925K added.
- The largest BioXcel Therapeutics seller in Q1 2019 was Artemis Investment Management, an estimated $1.5M sold.
Based on aggregated 13F filings for Q1 2019.